were derived from MCF-7 wt cells following prolonged exposure to 10 nM or 10 µM CJM 126 respectively.
Efforts to elucidate biochemical mechanisms conferring acquired resistance are reported herein. We have compared in the three cell lines the effects of exposure to 2-(4-aminophenyl)benzothiazoles on growth and DNA integrity. Evidence for cross-resistance to tamoxifen, BP, DNA damaging agents cisplatin, mitomycin C, the DNA intercalating agent doxorubicin and the antibiotic inhibitor of RNA synthesis actinomycin D has been studied, together with expression of genes purported to play a key role in cell survival. Depletion of CJM 126 from nutrient media, its biotransformation, intracellular distribution and the roles of xenobiotic metabolizing enzymes (NAT1, NAT2 and CYP1A1) have also been considered.
MATERIALS AND METHODS
CJM 126, DF 129, DF 203 and DF 229 were synthesized according to published methods (Shi et al, 1996) . Stock solutions of drugs (10 mM) were prepared in DMSO and stored, protected from light at 4°C for 4 weeks. RPMI 1640 tissue culture medium was obtained from Gibco (Paisley, UK). Foetal calf serum (FCS) was purchased from Globepharm (Esher, Surrey, UK). BDH (Merck, Poole, Dorset, UK) supplied fluorochrome mounting medium. NAT1 and NAT2 1°antibodies (abs), raised in rabbits were donated by Dr Lesley Stanley; specific abs directed against wt p53 (clones PAb 1801 and D-01), mutant p53 (clone PAb 240) and bcl-2 (clone 4D7) were purchased from Amersham (Bucks, UK). Anti-rabbit, anti-mouse 2°abs and reagents for enhanced chemiluminescence (ECL) detection were supplied by Pierce (Rockford, Illinois, USA). Abs (1°, 2°) specific for CYP1A1 detection, as well as the positive control sample of CYP1A1 microsomes were obtained from Gentest Corporation (Woburn, MA, USA). All other reagents were purchased from Sigma (Poole, Dorset, UK).
MCF-7 cells were cultivated in RPMI 1640 medium containing 2 µM L-glutamine and supplemented with 10% FCS, 100 IU ml -1 penicillin and 100 mg ml -1 streptomycin in an atmosphere of 5% CO 2 . Cells were subcultured twice weekly to maintain logarithmic growth. Variant cell lines were derived from wt following permanent culture in media containing either 10 nM or 10 µM CJM 126. Media was replaced twice weekly until proliferating colonies were established. Thereafter, MCF-7 10 nM 126 and MCF-7 10 µM 126 cell lines were routinely subcultured twice weekly in the continued presence of CJM 126.
In vitro growth inhibitory assays
To investigate the effect of agents on growth of MCF-7 sub-lines cells were seeded into 96-well microtitre plates at densities of 5 × 10 3 per well. Once adhered, cells were treated with test agent; final concentration range between 0.1 nM and 100 µM (n = 8). MTT conversion assays, performed at the time of drug addition and following 72 h exposure, monitored cell growth and viability. Water-soluble 3-(4,5-dimethylthiazol-2-y1)-2,5-diphenyl tetrazolium bromide (MTT, final concentration 400 µg ml -1 ) was added to each well. The following 4 h incubation allowed metabolism of MTT by mitochondrial dehydrogenases of viable cells to form an insoluble formazan product. Medium was aspirated and formazan solubilized by addition of DMSO (100 µl) and glycine buffer (25 µl). Absorbance, as a measure of viable cell number, was read at 550 nm on an Anthos Labtec systems plate reader. The efficacy of each agent reported was examined at least three times.
HPLC anaysis
Medium supporting cell growth was collected (n = 3) and protein precipitated by addition of HPLC-grade acetonitrile (600 µl) to 300 µl medium. Samples were microcentrifuged at 13 000 rpm for 5 min and supernatant (20 µl, n = 2) analysed by HPLC. Separation occurred on a Hypersil ODS reversed phase column (100 mm × 4.6 mm internal diameter) using a mobile phase of 65% methanol and 35% distilled water delivered at a rate of 1 ml min -1 . Benzothiazoles and derivatives were detected by UV at 330 nm. The identities of major biotransformation products were confirmed by chromatographic analyses of authentic samples.
Confocal laser scanning microscopy
Cells were seeded into sterile petridishes containing a single sterile coverslip in 10 ml media. They were allowed 24 h to attach before additional drug was administered to give a final concentration of 30 µM CJM 126. After 24 h exposure, cells were washed five times in sterile PBS and the coverslips drained. They were mounted onto glass slides using fluoromount and stored at 4°C in the dark. Specimens were examined using a Leica TCS4D confocal laser scanning microscope and UV laser. Images were stored on an optical disc (230 mb) and photographs produced using a Sony colour video printer. Parameters, including laser intensity, brightness and pinhole diameter were constant.
Fluorometric analysis of DNA unwinding
The method adopted for the detection of DNA strand-breaks utilises the observation that the rate of unwinding of the two DNA strands in alkali is related to the covalent length of the strands. Applications of this sensitive and rapid technique include prediction of sensitivity to xenobiotics (Birnboim and Jevcak, 1981) . The fluorescent dye ethidium bromide was used as a direct probe of DNA structure. Total fluorescence from the presence of doublestranded DNA plus contaminants was determined. Blank samples were sonicated lightly and treated with alkali under conditions which induced complete unwinding of low molecular weight double-stranded DNA. The difference between these two samples provided an estimate of the amount of double-stranded DNA. Experimental samples, including untreated cells and cells exposed to test agents, were used to estimate the rate of DNA unwinding. Cell extracts were exposed to alkaline conditions for 1 h, sufficient to permit partial unwinding of DNA. Fluorescence was read on a Perkin-Elmer LS-5 luminescence spectrometer: λem 520 nm, λex 590 nm. Samples were measured in triplicate within each experiment; experiments were performed at least three times. The rate of DNA unwinding in control and treated samples was measured, allowing agent-induced DNA strand-breaks to be determined.
Western blot procedures
For the detection of NAT1 and NAT2, MCF-7 wt , MCF-7 10 nM 126 and MCF-7 10 µM 126 cytosolic lysates were prepared and 30 µg protein loaded onto 12% denaturing polyacrylamide gels. Electrophoresis was performed at a constant current of 0.06 A for 1 h. Separated proteins were transferred to polyvinylidene fluoride (PVDF) membranes (100 v, 1 h) then probed for NAT1 or NAT2 proteins. Immunoblotting with specific abs for wt or mutant p53 and bcl-2 was carried out following separation of proteins (40 µg) from whole-cell lysates on 10% gels. Incubation with 2°ab linked to horseradish peroxidase then luminol enhancer:stable peroxide (1:1) preceeded detection by ECL. Separation (10% gels) of 40 µg cellular proteins preceeded detection of CYP1A1 bands. Membranes were incubated (2 h) with goat anti-human polyclonal 1°ab (1: 500 in PBS 0.02%T, 1% milk), immersed in alkaline phosphatase conjugated rabbit anti-goat 2°ab (1: 5000, 1 h) and incubated for 10 min with BCIP and NBT substrates in alkaline phosphatase buffer.
Protein bands were subjected to densitometry using a Sharp JX330P scanner.
Assay for ethoxyresorufin O-deethylase (EROD) activity
Cells were grown in 75 cm 3 flasks and lysates prepared following desired treatments. Protein content was determined by the method of Bradford (1976) . Reaction mixtures consisting of 760 µl TrisHCl buffer (pH 7.4, 100 mM), 10 µl MgCl 2 (5 mM), 100 µl homogenate (5 mg ml -1 ), 100 µl ethoxyresorufin (1 mM) were pre-incubated for 5 min at 37°C. Addition of 10 µl NADPH (50 mM) initiated reactions. Blank incubates lacked NADPH. Following incubation (30 min, 37°C), reactions were terminated by addition of ice-cold acetonitrile. Samples were centrifuged at 13 000 rpm for 5 min before analysis of supernatant. Fluorescence was read on a Perkin-Elmer LS-5 luminescence spectrometer: λem 530 nm, λex 585 nm. Samples were measured in triplicate within each experiment; experiments were performed three times.
RESULTS

In vitro growth inhibition
The unconventional biphasic dose-response relationship following treatment of MCF-7 wt cells with CJM 126 led to the hypothesis that the mechanism of action may be multifaceted. Thus, two variant cell lines have been established following longterm culture of MCF-7 wt cells with: (i) a concentration of CJM 126 within the growth inhibitory phase of the dose-response curve (10 nM); (ii) a concentration within the proliferative phase of the curve (10 µM). Six months' continuous exposure to 10 nM or 10 µM CJM 126 gave rise to proliferating MCF-7 colonies which were able to resist the growth-inhibitory effects of this compound. (Table 1) . Sensitivity to tamoxifen, BP, doxorubicin, mitomycin C and actinomycin D was retained by 10 nM 126 and MCF-7 10 µM 126 sublines. In addition, the 3 MCF-7 variant cell lines demonstrated equi-resistance to cisplatin.
Depletion from media of CJM 126 and its biotransformation by MCF-7 sublines
HPLC detection of CJM 126 enabled comparison of its disappearance from culture media nurturing MCF-7 cell lines. CJM 126 (30 µM) remained stable in medium alone (> 30 days at 37°C, Figure   3A ) providing a standard mean peak area and indicating that drug depletion from media was a consequence of accumulation or biotransformation within cells.
CJM 126 was rapidly depleted from media sustaining MCF-7 wt and MCF-7 10 µM 126 cells (84% and 93% depletion in 72 h, Figure  3A ). In contrast, 10 nM 126 cultures removed CJM 126 from medium at a much slower rate revealing 32% loss after 72 h incubation. All three cell lines metabolized CJM 126 ( Figure 3B ). HPLC chromatograms revealed distinct preferred routes of biotransformation of CJM 126 by 10 nM 126 and MCF-7 10 µM 126 cells. Like MCF-7 wt , the major biotransformation product liberated into MCF-7 10 nM 126 culture medium was 2-(4-acetylaminophenyl)benzothiazole (DF 128). After 72 h incubations, calculations from mean peak areas indicated an Cells were seeded at a density of 5 × 10 3 per well and challenged with agent as described in methods (n = 8). MTT assays (≥ 3 per drug) following 72 h exposure assessed cell growth and viability. Mean IC 50 values are given, standard errors ≤12% Acquired resistance to 2-(4-aminophenyl)benzothiazole 273
British Journal of Cancer (2000) 10 µM 126 culture medium however, the major biotransformation product detected was 2-(4-aminophenyl)-6-hydroxybenzothiazole (6-OH 126, Figure 1) . Following 72 h incubation, the approximate concentration of this metabolite detected in nutrient medium was 5 µM. Such oxidation deprived CJM 126 of growth inhibitory properties (IC 50 > 10 µM). regions. Fluorescence intensity was significantly reduced in both acquired-resistant cell lines. CJM 126 was largely restricted to the cytoplasm of MCF-7 10 nM 126 cells, but accessed nuclei of MCF-7 10 µM 126 cells.
Intracellular drug distribution
DNA integrity
The rate of DNA unwinding, accurately representing DNA strandbreaks accrued by MCF-7 populations, was monitored after 24 h and 72 h exposure to benzothiazole concentrations between 0.01 and 100 µM. MCF-7 wt cells accumulated greatest damage. After 24 h treatments, the biphasic dose-response relationship ( Figure  2 ) was reflected in rates of DNA unwinding: for example maximum strand-breaks followed exposures of 0.3 µM and ≥ 50 µM (results not shown). Figure 5 compares DNA unwinding in MCF-7 populations following 30 µM benzothiazole exposure for 72 h, prior to death of MCF-7 wt cells. Significantly reduced strand-breaks were incurred by the two MCF-7 variant populations. In particular, damage to MCF-7 10 nM 126 cells appeared negligible upon benzothiazole treatment.
Protein expression
Western blot experiments demonstrated expression of both NAT1 and NAT2 proteins in all three MCF-7 cell lines. Significantly enhanced (> 170% compared to MCF-7 wt ) expression of NAT2 protein was detected within the cytoplasm of MCF-7 10 nM 126 cells ( Figure 6A ), consistent with their superior acetylation efficacy. CYP1A1 expression was powerfully induced in MCF-7 wt and MCF-7 10 nM 126 cells by 50 µM CJM 126 (72 h). However, constitutive expression of CYP1A1 was detected only in MCF-7 10 µM 126 cells, whether cultured routinely in the presence of 10 µM CJM 126 ( Figure 6B lysates respectively was 23-fold and 27-fold greater than untreated MCF-7 wt cells, which expressed very low basal levels of wt p53 ( Figure 6A ).
CYP1A1 activity in MCF-7 lysates
Ethoxyresorufin O-de-ethylation is catalyzed by CYP1A1. CYP1A1 activity was assessed by measurement of reaction product resorufin. Negligible EROD activity was detected in untreated MCF-7 wt lysates following 30 min incubation at 37°C. Incubates containing MCF-7 10 nM 126 lysates produced low levels of resorufin. Significant constitutive CYP1A1 activity in Figure 7) . Activity was further induced in MCF-7 10 nM 126 and MCF-7 10 µM 126 incubates by 260% and 42% respectively.
DISCUSSION
Two MCF-7 sub-lines have been established which display resistance to the prototype analogue of an intriguing and unique class of antitumour agent, the 2-(4-aminophenyl)benzothiazoles. Acquired resistance to CJM 126 conferred cross-resistance to 3′ substituted analogues (Table 1 ). In the NCI COMPARE program Pearson Correlation Coefficients above 0.7 were observed only between 2-(4-aminophenyl)benzothiazole analogues (Bradshaw et al, 1998b) . Such observations indicate shared mechanisms of action. Evolution of resistance requires that sensitive cells acquire multiple genetic and biochemical modifications (Hayes and Wolf, 1990) We have shown that cells lines inherently sensitive to this class of agent rapidly sequester and metabolize 2-(4-aminophenyl)benzothiazoles, whereas no net uptake was detected by intrinsically resistant cell lines Kashiyama et al 1999) . Compared with MCF-7 wt and MCF-7 10 µM 126
, MCF-7 10 nM 126 cells, selected in the presence of the more cytotoxic concentration of 10 nM CJM 126, demonstrated dramatically impaired depletion of CJM 126 from media ( Figure 3A ) with predominantly cytoplasmic intracellular drug localization (Figure 4) . Accordingly, negligible DNA strand-breaks were incurred by this sub-line when challenged with 2-(4-aminophenyl)benzothiazole analogues ( Figure 5 ) reflecting their poor sensitivity. Access to nuclei may be essential for CJM 126-induced growth inhibition in MCF-7 wt ; nuclear exclusion by MCF-7 10 nM 126 may aid emergence of resistance.
However, cells selected in the presence of 10 µM CJM 126 (the proliferative phase) rapidly depleted culture medium of CJM 126 ( Figure 3A) , accumulated CJM 126-associated fluorescence within nuclei (Figure 4 ) and sustained levels of DNA strandbreaks greater than MCF-7 10 nM 126 but less than MCF-7 wt ( Figure 5 ). The major biotransformation product of CJM 126 extruded by MCF-7 wt cells is DF 128 (Figure 1 ). Activity was retained in MCF-7 wt , but with diminished potency. Cross-resistance to DF 128 was observed in both MCF-7 variant cell lines. Similarly, acetylation was the major metabolic route of CJM 126 in MCF-7 10 nM 126 cells. Consistant with this observation, cytoplasmic levels of NAT1 and particularly NAT2 proteins were elevated in the MCF-7 10 nM 126 sub-line.
In humans, NAT1 and NAT2 isoenzymes catalyse N-acetylation, O-acetylation and N-O-transacetylation of arylamines (Sadrieh et al, 1996) . Two polymorphic loci on chromosome 8p22 encode these enzymes segregating individuals into fast and slow acetylator phenotypes (Stacey et al, 1996) . Thus, acetylation capacity and the balance between xenobiotic activation/detoxification is subject to individual variation and, with it, the response to chemotherapeutic agents. Continued exposure of MDA 468 cells, which express only NAT1, to 10 nM or 10 µM CJM 126 has failed to generate resistant variants of this cell line, supporting a role for NAT2 in acquired resistance to CJM 126.
Biotransformation via C-oxidation was the preferred metabolic route of CJM 126 by 10 µM 126 cells; 6-OH 126 was the major metabolite rapidly detected in nutrient medium.
The role of enzymes responsible for C-oxidation, specifically CYP1A1 (Pelkonen and Raunio, 1997; Kress and Greenlee, 1997) has been investigated. CYP1A1 catalyzes both detoxification and activation of xenobiotics and precarcinogens (Crofts et al, 1998) . Recombinant CYP1A1 catalyzed C-6 oxidation of the benzothiazole nucleus (Chua et al, submitted) producing metabolites which: (i) like α-naphthoflavone and apigenin (Pastrakuljic et al, 1997) , inhibit CYP1A1 activity and abrogate growth inhibition induced by 2-(4-aminophenyl)benzothiazoles; (ii) like apigenin, evoke a mitogenic response between concentrations of 300 nM and 5 µM in MCF-7 wt cells. Covalent binding between 14 C labelled DF 203 and CYP1A1 further implicated this isoform as a molecular target for this class of agent. Moreover, in a panel of cell lines examined induction of CYP1A1 expression and activity by 2-(4-aminophenyl)benzothiazole was restricted to cell lines inherently sensitive to this class of agent. Significant induction by CJM 126 of CYP1A1 expression and activity was detected in MCF-7 wt and MCF-7 10 nM 126 lysates ( Figure 6B and 7) . However, oxidized derivatives comprised only minor biotransformation products of CJM 126 incubations with MCF-7 wt and MCF-7
10 nM 126 cells. The stable constitutive expression and activity of CYP1A1 in MCF-7 10 µM 126 cells may equip this sub-line with the ability to biotransform potentially damaging agents to non-toxic derivatives possessing growth-promoting stimuli which may assist survival of 10 µM 126 cells in the presence of 2-(4-aminophenyl)benzothiazole. Alternatively, meagre inducibility of CYP1A1 expression and activity in this cell line could lead to failure in activation of and MCF-7 10 µM 126 cells. Resorufin product was measured and means ± standard deviations of two representative experiments (n = 6) are shown.
2-(4-aminophenyl)benzothiazole and thus contribute to drug resistance. Ivy et al (1988) report low inducibility of CYP1A1 in multidrug-resistant MCF-7/Adr cells; indeed this cell line failed to respond to CJM 126 and in lysates prepared from CJM 126 treated cells, no expression of CYP1A1 protein was observed (data not shown).
The response of MCF-7 10 nM 126 and MCF-7 10 µM 126 cells to BP, the precarcinogen catalyzed to its reactive metabolite by CYP1A1, was of interest considering the implicated role of CYP1A1 in the mechanism of action of 2-(4-aminophenyl)benzothiazoles. In fact, marginally greater sensitivity was displayed by 10 nM 126 and MCF-7 10 µM 126 cell lines indicating distinct mechanisms of resistance to CJM 126 and BP in MCF-7 sub-lines. Acquired resistance to BP was mediated by decreased activation to (+/-)-antibenzo[a]pyrene-7, 8-diol, 9, 10-oxide (Caruso and Batist, 1999) . The three MCF-7 variant lines appeared resistant to the DNAdamaging effects of cisplatin, but displayed equi-sensitivity to mitotmycin C which cross-links and alkylates DNA. MCF-7 10 nM 126 and MCF-7 10 µM 126 sub-lines also retained sensitivity to doxorubicin and actinomycin D. Comparative genomic hybridization experiments confirmed under-representation of the MDR1 region (7q21) in both resistant cell lines (L Hiorns, personal communication); inferring that acquired resistance to CJM 126 is not mediated by p-glycoprotein overexpression.
Deregulation of apoptotic machinery may serve as a novel mechanism of resistance by influencing the propensity of cells to undergo drug-induced apoptosis. In MCF-7 wt cells exposed to 2-(4-aminophenyl)benzothiazoles, induction of wt p53 expression is concentration-dependent, biphasic and inversely proportional to growth inhibition and bcl-2 expression. Both MCF-7 10 nM 126 and MCF-7 10 µM 126 variants exhibit greatly enhanced levels of wt p53. Elevated p53 may promote survival in the presence of cytotoxins by arresting cells in the G 1 cell cycle phase, permitting repair of damaged DNA such that cells, rescued from the apoptotic pathway, are offered a growth advantage in the presence of the survival signal provided by enhanced bcl-2 expression (Malcomson et al, 1995; Kinzler and Vogelstein, 1994) . However, sensitivity to 2-(4-aminophenyl)benzothiazoles does not depend upon functional p53 or bcl-2 expression as exemplified by the equi-sensitive human breast carcinoma cell line MDA 468. Failure of these cells, which possess mutant p53 and are bcl-2 null, to spawn acquired resistant phenotypes may signify a role for these proteins in acquired resistance.
In conclusion, it is worth stressing that anti-cancer drug resistance is a multifactorial phenomenon. Decreased intracellular drug levels (anthracyclines, vinca alkaloids and antibiotics), increased drug inactivation (alkylating agents and antimetabolites), altered expression of drug metabolizing enzymes, target enzymes or receptors (methotrexate or steroids), all exemplify strategies which may have been adopted by MCF-7 cells as they acquire resistance to 2-(4-aminophenyl)benzothiazoles.
Knowledge of acquired resistance mechanisms may serve as an important prerequisite in novel drug discovery programmes to guide rational chemical synthesis of superior analogues. Hydrogen atoms in the benzothiazole nucleus have been isosterically replaced with fluorine atoms to eliminate inactivating 6-hydroxylation and hence proliferation associated with drug exposures between 1 µM and 30 µM (unpublished). In preliminary studies, a fluorinated derivative of CJM 126 elicited nM IC 50 values in MCF-7 wt , MCF-7 10 nM 126 and MCF-7 10 µM 126 cell lines. Moreover, the second proliferative phase associated with MCF-7 exposure to CJM 126 was absent, indicating that by molecular modification, acquired resistance to CJM 126 may be circumvented.
